

■ Information Letter No. 10

It is a great pleasure to present you the 10th Information Letter of the ELN. Topics of the current issue range from basic research to diagnostics all the way to leukemia therapy. It also contains the latest news from the ELN Foundation and EUTOS, about current trials in the European Leukemia Trial Registry, and summaries of the most important clinical results from oral presentations of the 55. ASH Annual Meeting and Exposition which were selected and precised by ELN experts. ▶ [Information Letter online](#)

■ MDS Pocket Card

Based on the recent publication of the European LeukemiaNet recommendations for the diagnosis and treatment of primary myelodysplastic syndromes in adults, the ELN developed a MDS pocket card. Ordering information and the pocket card in PDF format are now available on the website. ▶ [MDS pocket card](#)

■ This is what the ELN looks like

For more than ten years now, scores of international experts have gathered in Mannheim in February for the Annual Symposium of the European LeukemiaNet. A group picture of this year's participants is now available online. ▶ [Group picture](#)

■ Publications from the Network (selected)

Acute lymphoblastic leukemia

- ▶ Kalender Atak Z et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. *PLoS Genet.* 2013 Dec;9(12):e1003997.
- ▶ Trinquand A et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. *J Clin Oncol.* 2013 Dec 1;31(34):4333-42.

Acute myeloid leukemia

- ▶ Amadori S et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). *J Clin Oncol.* 2013 Dec 10;31(35):4424-30.
- ▶ Bertoli S et al. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. *Haematologica.* 2014 Jan;99(1):46-53.
- ▶ Breccia M et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. *Haematologica.* 2013 Dec;98(12):e161-3.
- ▶ Kohlmann A et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. *Leukemia.* 2014 Jan;28(1):129-37.
- ▶ Krupka C et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. *Blood.* 2014 Jan 16;123(3):356-65.
- ▶ Martínez-Cuadrón D et al. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. *Ann Hematol.* 2014 Jan;93(1):43-6.
- ▶ Willemze R et al. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. *J*

Chronic myeloid leukemia

- ▶ Bonifacio M et al. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. *Ann Hematol.* 2014 Jan;93(1):163-4.
- ▶ Grinfeld J et al. A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. *Br J Haematol.* 2013 Dec;163(5):631-9.
- ▶ Hochhaus A et al. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. *J Cancer Res Clin Oncol.* 2013 Dec;139(12):1971-84.
- ▶ Jabbour E et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). *Blood.* 2014 Jan 23;123(4):494-500.
- ▶ Johnson-Ansah H et al. Tolerability and efficacy of pegylated interferon- α -2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. *Cancer.* 2013 Dec 15;119(24):4284-9.
- ▶ Kalmanti L et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. *Ann Hematol.* 2014 Jan;93(1):71-80.

Chronic lymphocytic leukemia

- ▶ Abrisqueta P et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. *Blood.* 2013 Dec 5;122(24):3951-9.
- ▶ Jeromin S et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. *Leukemia.* 2014 Jan;28(1):108-17.
- ▶ Weissmann S et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. *Leukemia.* 2013 Dec;27(12):2393-6.

Myelodysplastic syndromes

- ▶ Neukirchen J et al. Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. *Leuk Res.* 2014 Jan;38(1):57-64.
- ▶ de Witte T. Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival? *Leuk Res.* 2013 Dec;37(12):1605.

Myeloproliferative neoplasms

- ▶ Barbui T et al. Masked polycythemia Vera (mPV): Results of an international study. *Am J Hematol.* 2014 Jan;89(1):52-4
- ▶ Cervantes F et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. *Blood.* 2013 Dec 12;122(25):4047-53.
- ▶ Finazzi G et al. Are MPNs vascular diseases? *Curr Hematol Malig Rep.* 2013 Dec;8(4):307-16.
- ▶ Lesteven E et al. Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms. *Blood.* 2014 Jan 30;123(5):794-6.

Stem cell transplantation

- ▶ Garnett C et al. Treatment and management of graft-versus-host disease: improving response and survival. *Ther Adv Hematol.* 2013 Dec;4(6):366-378.
- ▶ Giebel S et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. *Eur J Cancer.* 2014 Jan;50(2):411-7.
- ▶ Marek A et al. The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. *Bone Marrow Transplant.* 2014 Jan;49(1):55-61.

- ▶ Sanz J et al. Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms. Biol Blood Marrow Transplant. 2013 Dec;19(12):1725-30.

Miscellaneous

- ▶ Coorevits P et al. Electronic health records: new opportunities for clinical research. J Intern Med. 2013 Dec;274(6):547-60.
- ▶ Doods J et al. A European inventory of common electronic health record data elements for clinical trial feasibility. Trials. 2014 Jan 10;15(1):18.

■ New trials in the ELTR

EXPAND Study of the JAK Inhibitor Ruxolitinib administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)(CINC424A2201)

CLBH589X2106 A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)

ELN Foundation
European ■ LeukemiaNet

Support the ELN Foundation ▶

European Leukemia Information Center
Dr. Nicola Gökbüget, Dr. Sina Hehn
University Hospital Frankfurt
Department of Medicine II | Theodor-Stern-Kai 7
60590 Frankfurt am Main | Germany

ELIC@em.uni-frankfurt.de | www.leukemia-net.org | [unsubscribe](#)